Paediatric Solid Tumour Biology and Therapeutics Group

Professor Louis Chesler’s group is investigating the genetic causes for the childhood cancers, neuroblastoma, medulloblastoma and rhabdomyosarcoma. 

Research, projects and publications in this group

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient cohorts can be defined by alterations in a single oncogene. We focus on the role of the MYCN oncogene, since aberrant expression of MYCNis very significantly associated with high-risk in all three diseases and implies that they may have a common cell-of-origin.

Elucidating the molecular signalling pathways that control expression of the MYCN oncoprotein and targeting these pathways with novel therapeutics is a major goal of the laboratory. We use a variety of innovative preclinical drug development platforms for this purpose.

Technologically, we focus on genetically engineered cancer models incorporating novel imaging (optical and fluorescent) modalities that can be used as markers to monitor disease progression and therapeutic response.

Our group has several key objectives:

  • Mechanistically dissect the role of the MYCN oncogene, and other key oncogenic driver genes in poor-outcome paediatric solid tumours (neuroblastoma, medulloblastoma, rhabdomyosarcoma).
  • Develop novel therapeutics targeting MYCN oncoproteins and other key oncogenic drivers
  • Develop improved genetic cancer models dually useful for studies of oncogenesis and preclinical development of novel therapeutics.
  • Use such models to develop and functionally validate optical imaging modalities useful as surrogate markers of tumour progression in paediatric cancer.

Professor Louis Chesler

Clinical Senior Lecturer/Group Leader:

Paediatric Solid Tumour Biology and Therapeutics Professor Louis Chesler (Profile pic)

Professor Louis Chesler is working to understand the biology of children’s cancers and use that information to discover and develop new personalised approaches to cancer treatment. His work focuses on improving the understanding of the role of the MYCN oncogene.

Researchers in this group

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6124

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3617

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4186

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 3501

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4361

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6118

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6021

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6196

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6258

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6121

Email: [email protected]

Location: Sutton

.

Phone: +44 20 8722 4527

Email: [email protected]

Location: Sutton

.

OrcID: 0000-0003-3977-7020

Phone: +44 20 3437 6109

Email: [email protected]

Location: Sutton

I obtained an MSci in Biochemistry from the University of Glasgow in 2018. In October 2018 I joined the labs of Dr Michael Hubank and Professor Andrea Sottoriva to investigate the use of liquid biopsy to monitor clonal frequency and emergence of resistance mutations in paediatric cancers.

.

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6358

Email: [email protected]

Location: Sutton

.

Phone: +44 20 3437 6131

Email: [email protected]

Location: Sutton

.

Email: [email protected]

Location: Sutton

Professor Louis Chesler's group have written 112 publications

Most recent new publication 1/2025

See all their publications

Vacancies in this group

Working in this group

Postdoctoral Training Fellow

  • Chelsea
  • Structural Biology
  • Salary Range: £38,700 - £45,500 per annum
  • Fixed term

Under the leadership of Claudio Alfieri, we are seeking to appoint a Postdoctoral Training Fellow to join the Molecular Mechanisms of Cell Cycle Regulation Group at the Chester Beatty Laboratories, Fulham Road in London. This project aims to investigate the molecular mechanisms of cell cycle regulation by macromolecular complexes involved in cell proliferation decisions, by combining genome engineering, proteomics and in situ structural biology. For general information on Post Doc's at The ICR can be found here. Key Requirements The successful candidate must have a PhD in cellular biochemistry and experience in Cryo-EM and CLEM is desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years Department/Directorate Information: The candidate will work in the Molecular Mechanisms of Cell Cycle Regulation Group within the ICR Division of Structural Biology headed by Prof. Laurence Pearl and Prof. Sebastian Guettler. The division has state-of-the-art facilities for protein expression and biophysics/x-ray crystallography, in particular the Electron Microscopy Facility is equipped with a Glacios 200kV with Falcon 4i detector with Selectris energy filter and the ICR has access to Krios microscopes via eBIC and the LonCEM consortium. We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Claudio Alfieri via Email on [email protected]

Postdoctoral Training Fellow – X-Ray Crystallography

  • Sutton
  • Hit Discovery & Structural Design
  • £45,600 - £51,450
  • Fixed term

A postdoctoral position is available in Dr Rob van Montfort’s Hit Discovery and Structural Design Team within the CCDD. The Post-doc will be involved in the structure determination of protein-ligand complexes, primarily by X-ray crystallography but also potentially by cryo-electron microscopy (cryoEM), as part of one of the CCDD’s drug discovery programmes. The postholder will be responsible for protein production and purification, protein crystallisation, structure determination by X-ray crystallography and subsequent structural analysis. The successful candidate will be an integral member of a multidisciplinary project team within the CCDD at the ICR Sutton site, and will interact closely with biologists, computational chemists, medicinal chemists, assay scientists and structural biologists.They will have access to state-of-the-art facilities for protein production and purification, as well as biophysical characterisation and crystallisation at the Sutton site. We also benefit from excellent access to Diamond Light Source synchrotron at the Harwell Science and Innovation campus, Didcot, UK, for X-ray data collection. Additionally, the successful candidate will also be part of the Division of Structural Biology, located in Chelsea, in which the structural biologists in Dr van Montfort’s team are also embedded, and will have access to its state-of-the art cryoEM facilities. These include an in-house Glacios and 30% direct access to a Titan KRIOS located at the Francis Crick Institute. Both microscopes are equipped with Falcon III detectors and volta phase plates (VPP). In addition, we have excellent access to the electron bioimaging Centre (eBIC) at the Harwell Science and Innovation campus, Didcot, UK. About you The successful candidate must have must have a PhD (or equivalent) in a biological or physical science, with demonstrable experience in X-ray crystallography and protein biochemistry. Experience in cryo-EM specimen preparation and data processing would be an advantage, though not strictly mandatory. Experience in molecular biology, protein expression and purification, as well as biophysical characterisation of protein samples would also be highly desirable. The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF (including previous employment at this level elsewhere). For general information on Postdocs at The ICR, more information can be found here. Department/Directorate Information The Institute of Cancer Research (ICR), London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievements dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, the ICR leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment. Together with our hospital partner The Royal Marsden, we are rated in the top four centres for cancer research and treatment worldwide. As well as being a world-class institute, we are a college of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework in 2014 and second in 2021 (REF 2014 and 2021). The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer. Department/Directorate Information: The Centre for Cancer Drug Discovery (CCDD), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The CCDD’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, structural biology, assay scientists, drug metabolism and clinical specialists. This is an exciting and fast-moving research setup and offers the opportunity to work within a multi-disciplinary environment using state-of-the-art techniques and equipment. What we offer A dynamic and supportive research environment Access to state-of-the-art facilities and professional development opportunities Collaboration with leading researchers in the field Competitive salary and pension We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr van Montfort [email protected] or Dr Le Bihan [email protected]. Please DO NOT send your application to Dr Van Montfort or Dr Le Bihan, but apply via the e-recruitment system on our websitewww.icr.ac.uk/careers.

Industrial partnership opportunities with this group

Opportunity: A novel test for predicting future cancer risk in patients with inflammatory bowel disease

Commissioner: Professor Trevor Graham

Recent discoveries from this group

11/03/25

​Professor Peter Garland CBE, who served as Chief Executive of the ICR from 1989 to 1999, passed away on 5 March.

Before becoming the ICR's Chief Executive, Professor Garland was the founding Head of the Biochemistry Department at the University of Dundee, Principal Scientist at Unilever Research, and Director of Research at Amersham International plc.

A lasting legacy at the ICR

Alongside his scientific achievements, Professor Garland has left a lasting legacy at the ICR. Under his leadership the ICR first received funding from the Higher Education Funding Council for England (HEFCE). This crucial funding from the Government continues to this day from an equivalent body called Research England. Under his leadership, the ICR was also able to increase staff numbers by around 40 per cent and he led the extension of the ICR's Chester Beatty Laboratories (CBL) in Chelsea and the expansion of the ICR's presence on the Sutton campus, which commenced in 1999.

Professor Garland's policy of innovative recruitment saw him bring on board Professor Laurence Pearl and Professor David Barford to jointly head the newly formed Division of Structural Biology, housed in the renovated CBL. This also incorporated the Biomolecular Structure Unit. Peter also appointed Professor Paul Workman, Harrap Professor of Pharmacology and Therapeutics, to lead drug discovery at the ICR. This resulted in the discovery of multiple personalised medicines. Professor Workman, following in Professor Garland's footsteps, later became Chief Executive of the ICR.

Professor Garland also supported Professor Sir Mike Stratton (now at the Wellcome Sanger Institute and a former Director of that institution) in his work in cancer gene discovery. In 1994, this resulted in funding from the ICR to set up a Cancer Gene Cloning Laboratory led by Professor Sir Mike and Professor Colin Cooper and enabled the discovery of the BRCA2 tumour susceptibility gene.

Extremely supportive and extraordinarily influential

He also played an important role as the Chair of Cambridge Antibody Technology (CAT) for many years. One of the UK's most important biotechnology companies, CAT developed the drug Humira that has had a major impact on the treatment of rheumatoid arthritis and Crohn's disease.

Professor Garland was recognised in the 1999 Queen's Birthday Honours with a Commander of the British Empire (CBE) for his services to cancer research and biotechnology.

Speaking about Professor Garland, Professor Paul Workman said:

"Like myself, Peter was trained in biochemistry and had spent some time in industry. I'm hugely grateful that Peter recruited me to the ICR in 1997 from Zeneca Pharmaceuticals to take over the then relatively small drug discovery group at Sutton. He was extremely supportive of my efforts to modernise and build up what is now the Centre for Cancer Drug Discovery and to switch the focus to precision medicines. He also encouraged the productive interaction between my cancer therapeutics centre and Chris Marshall's centre for cell and molecular biology."

Professor David Barford added:

"I'm grateful to Peter for recruiting me and Laurence Pearl to establish a new Section of Structural Biology at the refurbished Chester Beatty Laboratories. The generous support provided allowed us to take on challenging research projects and to collaborate on drug discovery projects with Paul Workman, Chris Marshall and Richard Marais and others. Peter's scientific vision and bold and persuasive recruitment style resulted in far-reaching scientific and medical advances, and positively influenced the careers of many. It is also thanks to Peter's vision as the first Professor of Biochemistry at Dundee University (and Head of Department) in recruiting Philip and Tricia Cohen, that I spent an earlier period of my scientific career in their labs."

Professor Sir Mike Stratton said:

"Peter Garland was an extraordinarily influential Chief Executive of The Institute of Cancer Research. With remarkable shrewdness, foresight, wisdom and determination he reshaped the Institute’s scientific portfolio, setting it on a path of success for decades to come. He was universally respected, and extremely important to me personally in his support and encouragement. I owe him a huge debt of gratitude and will never forget his quiet, but indomitable spirit and vision."